The NK-1 antagonist, Fosaprepitant, versus Ondansetron for prevention of postoperative nausea and vomiting

Trial Profile

The NK-1 antagonist, Fosaprepitant, versus Ondansetron for prevention of postoperative nausea and vomiting

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2015

At a glance

  • Drugs Fosaprepitant (Primary) ; Ondansetron
  • Indications Postoperative nausea and vomiting
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Aug 2015 Status changed from recruiting to completed, as reported by University Hospital Medical Information Network - Japan.
    • 22 Jan 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
    • 07 Sep 2013 Planned number of patients changed from 60 to 200 as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top